{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T16:14:32Z","timestamp":1785600872293,"version":"3.56.0"},"reference-count":20,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100002770","name":"Food Safety Commission of Japan","doi-asserted-by":"publisher","award":["JPCAFSC20202006"],"award-info":[{"award-number":["JPCAFSC20202006"]}],"id":[{"id":"10.13039\/501100002770","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science Grant-in-Aid for Young Scientists","doi-asserted-by":"publisher","award":["202021210"],"award-info":[{"award-number":["202021210"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["DMBL"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec><jats:title>Aim:<\/jats:title><jats:p>The main aim of the current study was to obtain forward dosimetry assessments of pyrrolizidine alkaloid senkirkine plasma and liver concentrations by setting up a human physiologically based pharmacokinetic (PBPK) model based on the limited information available.<\/jats:p><\/jats:sec><jats:sec><jats:title>Background:<\/jats:title><jats:p>The risks associated with plant-derived pyrrolizidine alkaloids as natural toxins have been assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>The pyrrolizidine alkaloid senkirkine was investigated because it was analyzed in a European transcriptomics study of natural hepatotoxins and in a study of the alkaloidal constituents of traditional Japanese food plants Petasites japonicus. The in silico human plasma and liver concentrations of senkirkine were modeled using doses reported for acute-term toxicity in humans.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Using a simplified PBPK model established using rat pharmacokinetic data, forward dosimetry was conducted. Since in vitro rat and human intrinsic hepatic clearances were similar; an allometric scaling approach was applied to rat parameters to create a human PBPK model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>After oral administration of 1.0 mg\/kg in rats in vivo, water-soluble senkirkine was absorbed and cleared from plasma to two orders of magnitude below the maximum concentration in 8 h. Human in silico senkirkine plasma concentration curves were generated after virtual daily oral administrations of 3.0 mg\/kg senkirkine (the dose involved in an acute fatal hepatotoxicity case). A high concentration of senkirkine in the culture medium caused in vitro hepatotoxicity as evidenced by lactate dehydrogenase leakage from human hepatocyte-like HepaRG cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Higher virtual concentrations of senkirkine in human liver and plasma than those in rat plasma were estimated using the current rat and human PBPK models. Current simulations suggest that if P. japonicus (a water-soluble pyrrolizidine alkaloid-producing plant) is ingested daily as food, hepatotoxic senkirkine could be continuously present in human plasma and liver.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1872312801666211220110055","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T05:04:47Z","timestamp":1640063087000},"page":"64-69","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Plasma Concentration Profiles for Hepatotoxic Pyrrolizidine Alkaloid Senkirkine in Humans Extrapolated from Rat Data Sets Using a Simplified Physiologically Based Pharmacokinetic Model"],"prefix":"10.2174","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1068-4261","authenticated-orcid":true,"given":"Hiroshi","family":"Yamazaki","sequence":"first","affiliation":[{"name":"Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kamiya","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Miura","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Airi","family":"Kato","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norie","family":"Murayama","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/jat.1504","volume":"30","author":"Chen T.","year":"2010","unstructured":"Chen T.; Mei N.; Fu P.P.; Genotoxicity of pyrrolizidine alkaloids. J Appl Toxicol 2010,30(3),183-196","journal-title":"J Appl Toxicol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1093\/jnci\/58.4.1155","volume":"58","author":"Hirono I.","year":"1977","unstructured":"Hirono I.; Mori H.; Yamada K.; Hirata Y.; Haga M.; Carcinogenic activity of petasitenine, a new pyrrolizidine alkaloid isolated from Petasites japonicus Maxim. J Natl Cancer Inst 1977,58(4),1155-1157","journal-title":"J Natl Cancer Inst"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1246\/cl.1976.461","volume":"5","author":"Yamada K.","year":"1976","unstructured":"Yamada K.; Tatematsu H.; Suzuki M.; Hirata Y.; Haga M.; Hirono I.; Isolation and the structures of two new Alkaloids, Petasitenine and neopetasteinine from Petasites japonica Maxim. Chem Lett 1976,5(5),461-464","journal-title":"Chem Lett"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0165-1218(79)90152-6","volume":"68","author":"Yamanaka H.","year":"1979","unstructured":"Yamanaka H.; Nagao M.; Sugimura T.; Furuya T.; Shirai A.; Matsushima T.; Mutagenicity of pyrrolizidine alkaloids in the Salmonella\/mammalian-microsome test. Mutat Res 1979,68(3),211-216","journal-title":"Mutat Res"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.18433\/J3BG7J","volume":"18","author":"Neuman M.G.","year":"2015","unstructured":"Neuman M.G.; Cohen L.; Opris M.; Nanau R.M.; Hyunjin J.; Hepatotoxicity of pyrrolizidine alkaloids. J Pharm Pharm Sci 2015,18(4),825-843","journal-title":"J Pharm Pharm Sci"},{"key":"ref=6","first-page":"469","volume":"63","author":"Hirono I.","year":"1979","unstructured":"Hirono I.; Haga M.; Fujii M.; Matsuura S.; Matsubara N.; Nakayama M.; Furuya T.; Hikichi M.; Takanashi H.; Uchida E.; Hosaka S.; Ueno I.; Induction of hepatic tumors in rats by senkirkine and symphytine. J Natl Cancer Inst 1979,63(2),469-472","journal-title":"J Natl Cancer Inst"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2131\/jts.9.143","volume":"9","author":"Mori H.","year":"1984","unstructured":"Mori H.; Kawai K.; Ohbayashi F.; Bunai Y.; Yamada K.; Hirono I.; Some toxic properties of a carcinogenic pyrrolizidine alkaloid, petasitenine. J Toxicol Sci 1984,9(2),143-149","journal-title":"J Toxicol Sci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/19440049.2017.1382726","volume":"35","author":"Mulder P.P.J.","year":"2018","unstructured":"Mulder P.P.J.; L&#xF3;pez P.; Castellari M.; Bodi D.; Ronczka S.; Preiss-Weigert A.; These A.; Occurrence of pyrrolizidine alkaloids in animal- and plant-derived food: Results of a survey across Europe. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2018,35(1),118-133","journal-title":"Food Addit Contam Part A Chem Anal Control Expo Risk Assess"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s11418-019-01285-9","volume":"73","author":"Kitajima M.","year":"2019","unstructured":"Kitajima M.; Okabe K.; Yoshida M.; Nakabayashi R.; Saito K.; Kogure N.; Takayama H.; New otonecine-type pyrrolizidine alkaloid from Petasites japonicus. J Nat Med 2019,73(3),602-607","journal-title":"J Nat Med"},{"key":"ref=10","first-page":"2406","volume":"9","year":"2011","unstructured":"Scientific opinion on Pyrrolizidine alkaloids in food and feed. EFSA J EFSA2011,9(11),2406","journal-title":"EFSA J"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s00204-020-02779-2","volume":"94","author":"Ebmeyer J.","year":"2020","unstructured":"Ebmeyer J.; Rasinger J.D.; Hengstler J.G.; Schaudien D.; Creutzenberg O.; Lampen A.; Braeuning A.; Hessel-Pras S.; Hepatotoxic pyrrolizidine alkaloids induce DNA damage response in rat liver in a 28-day feeding study. Arch Toxicol 2020,94(5),1739-1751","journal-title":"Arch Toxicol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00216-011-5075-3","volume":"401","author":"Wang C.","year":"2011","unstructured":"Wang C.; Li Y.; Gao J.; He Y.; Xiong A.; Yang L.; Cheng X.; Ma Y.; Wang Z.; The comparative pharmacokinetics of two pyrrolizidine alkaloids, senecionine and adonifoline, and their main metabolites in rats after intravenous and oral administration by UPLC\/ESIMS. Anal Bioanal Chem 2011,401(1),275-287","journal-title":"Anal Bioanal Chem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2131\/jts.46.391","volume":"46","author":"Yanagi M.","year":"2021","unstructured":"Yanagi M.; Kamiya Y.; Murayama N.; Banju K.; Shimizu M.; Yamazaki H.; Metabolic profiles for the pyrrolizidine alkaloid neopetasitenine and its metabolite petasitenine in humans extrapolated from rat in vivo and in vitro data sets using a simplified physiologically based pharmacokinetic model. J Toxicol Sci 2021,46(9),391-399","journal-title":"J Toxicol Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1021\/acs.chemrestox.1c00249","volume":"34","author":"Kamiya Y.","year":"2021","unstructured":"Kamiya Y.; Handa K.; Miura T.; Ohori J.; Shimizu M.; Kitajima M.; Shono F.; Funatsu K.; Yamazaki H.; An updated in silico prediction method for volumes of systemic circulation of 323 disparate chemicals for use in physiologically based pharmacokinetic models to estimate plasma and tissue concentrations after oral doses in rats. Chem Res Toxicol 2021,34(10),2180-2183","journal-title":"Chem Res Toxicol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/toxsci\/kfn190","volume":"106","author":"Edwards S.W.","year":"2008","unstructured":"Edwards S.W.; Preston R.J.; Systems biology and mode of action based risk assessment. Toxicol Sci 2008,106(2),312-318","journal-title":"Toxicol Sci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1021\/tx0496690","volume":"18","author":"Hayes K.R.","year":"2005","unstructured":"Hayes K.R.; Bradfield C.A.; Advances in toxicogenomics. Chem Res Toxicol 2005,18(3),403-414","journal-title":"Chem Res Toxicol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2131\/jts.45.695","volume":"45","author":"Miura T.","year":"2020","unstructured":"Miura T.; Kamiya Y.; Hina S.; Kobayashi Y.; Murayama N.; Shimizu M.; Yamazaki H.; Metabolic profiles of coumarin in human plasma extrapolated from a rat data set with a simplified physiologically based pharmacokinetic model. J Toxicol Sci 2020,45(11),695-700","journal-title":"J Toxicol Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"114749","DOI":"10.1016\/j.bcp.2021.114749","volume":"192","author":"Kamiya Y.","year":"2021","unstructured":"Kamiya Y.; Omura A.; Hayasaka R.; Saito R.; Sano I.; Handa K.; Ohori J.; Kitajima M.; Shono F.; Funatsu K.; Yamazaki H.; Prediction of permeability across intestinal cell monolayers for 219 disparate chemicals using in vitro experimental coefficients in a pH gradient system and in silico analyses by trivariate linear regressions and machine learning. Biochem Pharmacol 2021,192,114749","journal-title":"Biochem Pharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1021\/tx500071q","volume":"27","author":"Ruan J.","year":"2014","unstructured":"Ruan J.; Yang M.; Fu P.; Ye Y.; Lin G.; Metabolic activation of pyrrolizidine alkaloids: Insights into the structural and enzymatic basis. Chem Res Toxicol 2014,27(6),1030-1039","journal-title":"Chem Res Toxicol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0165-1218(80)90027-0","volume":"78","author":"Takanashi H.","year":"1980","unstructured":"Takanashi H.; Umeda M.; Hirono I.; Chromosomal aberrations and mutation in cultured mammalian cells induced by pyrrolizidine alkaloids. Mutat Res 1980,78(1),67-77","journal-title":"Mutat Res"}],"container-title":["Drug Metabolism and Bioanalysis Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1872312801666211220110055","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/199151\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1872312801666211220110055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T22:08:13Z","timestamp":1726351693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/199151\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1872312801666211220110055","relation":{},"ISSN":["2949-6810"],"issn-type":[{"value":"2949-6810","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-09-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}